# Ni-MOF@Fe-CDs Nanozyme Enables Dual-Signal Uric Acid Detection at 0.072 μM Limit

> Discover the Ni-MOF@Fe-CDs nanozyme for dual-mode uric acid detection. Achieve 0.072 μM LOD and 92.2 - 107.6% recovery in urine - ideal for clinical diagnostics and bioanalytical research.

- Canonical URL: https://coreiten.com/en/article/ni-moffe-cds-nanozyme-enables-dual-signal-uric-acid-detection-at-0072-μm-limit
- Language: en
- Section: Physics Chemistry
- Author: Sami
- Published: 2026-03-19T06:23:58+03:00
- Modified: 2026-03-19T06:23:58+03:00
- Publisher: CoreITen (https://coreiten.com)
- Keywords: Ni-MOF@Fe-CDs nanozyme, uric acid detection, ratiometric fluorescence sensor, peroxidase-like activity, point-of-care uric acid testing

---

Ni-MOF@Fe-CDs nanozyme probe revolutionizes uric acid detection with dual colorimetric and ratiometric fluorescence signals, achieving a detection limit of 0.072 μM. Led by Chunyan Yan, Bowen Yu, and Ping Qiu, this innovation loads iron-carbon dots onto Ni-MOF nanoflowers for superior peroxidase-like activity.

Chemists and bioanalysts targeting precise biomarkers in clinical samples gain a tool for rapid, visual uric acid quantification, enabling early gout diagnosis and metabolic disorder monitoring.

The probe generates hydroxyl radicals (•OH) from H2O2, confirmed by electron paramagnetic resonance, with steady-state kinetics showing Km of 1.18 mM and Vmax of 9.82 × 10 - 8 M•s - 1. This outperforms traditional enzymes in stability and cost.

### Nanozyme Design and Catalytic Mechanism

Fe-CDs integrate into Ni-MOF petals, enhancing electron transfer for efficient H2O2 decomposition. The peroxidase-mimicking activity oxidizes o-phenylenediamine (OPD) in the presence of H2O2 produced from uric acid via uricase.

2,3-Diaminophenazine (DAP) from OPD oxidation quenches Ni-MOF@Fe-CDs fluorescence at 430 nm via inner filter effect (IFE), dominating 85.2% of quenching efficiency. This ratiometric shift (FI565/FI430) ensures self-calibrating, interference-resistant detection.

For researchers in analytical chemistry, this dual-function platform verifies results across modes, reducing false positives in complex matrices like urine where uric acid levels signal health risks such as gout or kidney injury.

### Performance in Real Samples

In human urine, recoveries range 92.2 - 107.6% with RSD <2.9%, matching clinical standards. The visual colorimetric mode suits point-of-care testing, while fluorescence offers lab-grade precision.

Compared to single-mode sensors, dual outputs provide mutual validation, critical for biomarkers like uric acid linked to multiple sclerosis disability and hypouricemia-related kidney issues.

### Broader Context and Significance

Uric acid monitoring matters in metabolism; elevated levels (>420 μM in men, >360 μM in women) precede gout, while lows indicate hereditary risks. Nanozyme tech like Ni-MOF@Fe-CDs scales production cheaply versus natural enzymes.

This advances from prior MOF sensors, such as Fe-Ni-MOF/RGO (LOD 0.021 μM electrochemical) or Fe3Ni-MOF-NH2 (24 nM ratiometric), by combining catalysis and fluorescence in one probe.

### My Take

With a 0.072 μM LOD and real-sample recoveries over 92%, Ni-MOF@Fe-CDs positions as a frontrunner for portable diagnostics, potentially slashing gout misdiagnosis rates that affect 4% globally. Its IFE-dominant quenching (85.2%) signals robust anti-interference, forecasting integration into wearables for continuous uric acid tracking amid rising metabolic diseases.

#### Frequently Asked Questions

**What is the detection limit of Ni-MOF@Fe-CDs for uric acid?** The limit is 0.072 μM in dual-mode detection.

**How does it perform in urine samples?** Recoveries are 92.2 - 107.6% with RSD <2.9%.

**What makes it dual-signal?** Colorimetric via OPD oxidation and ratiometric fluorescence via DAP quenching of Fe-CDs emission.

## Sources

- [link.springer.com](https://link.springer.com/article/10.1007/s00216-026-06422-4?error=cookies_not_supported&code=aeaeaba7-fdb5-42bf-b595-9737ecad6d60)